** Shares of Sichuan Kelun-Biotech Biopharmaceutical 6990.HK jump 10% to HK$418, on course for the biggest one-day pct gain since March 27, 2025
** Stock hit the highest level since February 23
** The China-based oncology and immunology drug producer said the National Medical Products Administration (NMPA) has approved the Investigational New Drug $(IND)$ application for SKB575/HBM7575, a long-acting bispecific antibody for the treatment of atopic dermatitis
** SKB575/HBM7575 is co-developed by the company and HBM Holdings 2142.HK
** Shares of HBM climb 4.8% to HK$12.06, on track for the biggest one-day pct rise since January 8
** YTD, HBM shares down 2%, while Sichuan Kelun-Biotech stock up 5.4%, Hang Seng Biotech Index .HSBIO up 3.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))